Actavis

  • Featured Story

    pharmaceutical stocks

    Antibiotic-resistant microorganisms are turning into a national medical nightmare, and the need for new, more effective medications to treat them has reached critical mass.

    In response, the U.S. government and the pharmaceutical industry are joining forces to handle the crisis - and extraordinary opportunities are beckoning the savvy investor.

    The Centers for Disease Control and Prevention (CDC) estimates that in the U.S. alone, antibiotic-resistant bacteria make 2 million people sick and 23,000 die each year.

    Estimates of the annual cost to the economy range up to $35 billion in excess medical expenses and another $35 billion in lost productivity.

    It's a problem that isn't going away. In fact, it's getting worse...

Article Index

These Pharma Companies Stand Between Us and the "Bacterial Apocalypse"

pharmaceutical stocks

Antibiotic-resistant microorganisms are turning into a national medical nightmare, and the need for new, more effective medications to treat them has reached critical mass.

In response, the U.S. government and the pharmaceutical industry are joining forces to handle the crisis - and extraordinary opportunities are beckoning the savvy investor.

The Centers for Disease Control and Prevention (CDC) estimates that in the U.S. alone, antibiotic-resistant bacteria make 2 million people sick and 23,000 die each year.

Estimates of the annual cost to the economy range up to $35 billion in excess medical expenses and another $35 billion in lost productivity.

It's a problem that isn't going away. In fact, it's getting worse...